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ABSTRACT  
Objective: To assess certain quality control parameters for seven brands of albendazole tablets obtained 
from different retail pharmacies. 
Methods: The physicochemical properties and active ingredientsofseven randomly selectedbrands of al-
bendazole tablets were assessed weight uniformity, hardness, friability, disintegration and dissolution 
Results: All seven albendazole brands met the British Pharmacopeia (BP) quality control standards of 
weight uniformity, friability and the active ingredient content. Five brands met the BP disintegration criteri-
on,whereas only two brands complied with the BP quality control parameters of the dissolution specifica-
tions. 
Conclusions: Out of the seven brands of albendazole (400 mg) tablets, only two fulfillthe BP quality control 
standards and show physicochemicalquivalence. This emphasizes the need for regular assessment of mar-
keted drugs to assure equivalenceof these drugs to their innovators. 
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One of the major health problems is parasitic 
infection, particularly in the third world coun-
tries. Moreover, it has been recognized that 
there is evidence of emerging resistance to all 
major animal anthelmintics. One of the most 
effective wide-spectrum anthelmintic agents is 
Albendazole (1). 
Selection of pharmaceutical products from 
several generic drug products having the same 
active ingredients is a matter of concern for 
healthcare practitioners. The first step to as-
sure therapeutic equivalence of any drug 
product involves assuring the chemical and bi-
opharmaceutical equivalence of such drug 
(2).In developing countries, assurance of quali-
ty and interchangeability of multisource drug 
products poses a challenge (3). Clinical re-
sponse variability and batch inconsistency 
among generic drugs have been reported (4). 
For instance, such discrepancy has been 
demonstrated among metformin and metroni-
dazole tablets (4). 
Most oral dosage forms rely heavily on in 
vitro dissolution studies to predict their in-
vivo bioavailability (6, 7). Drug dissolution 
testing not only plays an essential role in the 
monitoring of batch-to-batch consistency but 
also acts as a surrogate parameter for in vivo 
bioavailability (8). As in other developing 
countries, few drug quality control studies 
have been conducted so far in Yemen (9-13). 
studies reported that such drugs are often ob-
tained irrespective of the quality standards. 
Moreover, drug quality standardization during 
purchasing is not implemented by non-
governmental organizations in such countries 
(14). 
 
The present study aimed to assess certain 
quality control parameters of seven brands of al-
bendazole tablets obtained from different regions 
of Yemen. The findings of the present study can be 
used as a source of information to drug manufac-
turers and drug regulatory authorities in the coun-
try. 
2. Methods 
2.1. Study design  
This was a comparative in-vitro study to assess a 
number of quality control parameters of albend-
azole tablet brands locally distributed in the Yem-
eni market, including weight variation, hardness, 
friability as well as disintegration and dissolution 
times of such brands. 
2.2. Sample collection and identification 
Albendazole tablets (400 mg) of seven commercial 
brands were conveniently purchased from phar-
macies in the Yemeni market. Six brands were in 
the form of uncoated compressed tablets, while the 
seventh brand was in the form of coated tablets. 
All the obtained tablets were coded with the let-
ters A to G (Table 1). These were stored according 
to manufacturers’ instructions prior to investiga-
tions, and codes were removed after performing 
the investigations. Study samples were collected in 
the period from 20 February to 20 March (2013) 
from four Yemeni governorates; namely, Sana’a, 
Ibb, Marib, and Hodeidah.  
2.3. Quality assessment procedures 
Different analytical quality control tests for the de-
velopment and manufacture of pharmaceutical 
formulations (15) were used for the assessment of 
albendazole tablet brands in the present study. 
These tests included: 
2.3.1. Weight variation test  
Ten tablets of each brand were weighed using an 
analytical weighing balance (OHUAS Adventurer®, 
New Jersey, USA; Model: AR2140). The average 
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weight and the percentage weight variation 
from the mean value were obtained for each 
brand. Appropriate tablet hardness and friabil-
ity is attributed to weight controlling within a 
tight range, where the percentage weight vari-
ation was ensured not to exceed 5% (16). The 
average weight variations for all brands of al-
bendazole tablets were calculated mathemati-
cally using the following equations (17):  
Highest weight variation = (Highest weight − Aver-
age weight/Average weight)  100 
Lowest weight variation = (Lowest weight − Aver-
age weight/Average weight)  100 
Table 1. Identity and specification of albendazole brands includ-










France A 314567 01-02-2012 01-02-2017 
India B 11al02 01-10-2011 01-09-2014 
India C Kw2748 01-10-2012 01-09-2015 
Yemen D 106t 01-02-2013 01-02-2016 
India E 180212 01-09-2012 01-10-2015 
Cyprus F 37909 01-09-2008 01-09-2013 
South Korea G 7903p 01-10-2009 01-10-2014 
* The strength of all brands was 400 mg. 
2.3.2. Hardness test 
The hardness of 10 tablets selected randomly 
from each brand was determined using a tab-
let breaking-strength tester (Germany, PHAR-
MA TEST: PTB). The hardness for each tablet 
was recorded, and the mean hardness was cal-
culated according to well-established equa-
tions (18). 
2.3.3. Friability test 
Five albendazole tablets were dusted and 
weighed together before friability testing us-
ing a US Pharmacopoeia (USP)-compatible fri-
abilator Germany (PHARMA TEST: PTB) which 
was set to run for four minutes at a speed of 25 
rounds per minute (rpm). After removing the 
tablets from the friabilator, they were 
dusted and re-weighed. Friability was calculated 
using the following equation (16): 
% Friability = (Wi – Wf) / Wi)  100 
Wi= weight of tablet before friability  
Wf = weight of tablet after friability 
Conventionally, compressed tablet weight loss 
was generally ensured to be less than 0.5 to 1% 
(17). 
2.3.4. Disintegration time test  
Disintegration time of uncoated tablets was de-
termined using a USP disintegration tester (Elec-
trolab, Mumbai, India; Model: ED-2L) in 0.1 N HCl 
medium at 37±1 °C according to the British Phar-
macopoeia (BP) (16). For each albendazole brand, 
six tablets were selected and placed in separate cy-
lindrical tubes in a basket rack. The time required 
for each tablet to disintegrate and pass out 
through the mesh was recorded, and the mean dis-
integration time for each brand was then calculat-
ed (19). 
2.3.5. Dissolution time test  
Drug release pattern during a specific period was 
determined by dissolution time testing (20). The 
drug release pattern for each brand of albendazole 
was determined using a dissolution tester (Pharma 
Test, Hainburg, Germany; Model: PT-DT70). The 
dissolution process was carried out in a medium of 
900 ml 0.1 N HCl using a speed of 50 rpm at 37±1 
°C. Up to three 5-ml samples were withdrawn eve-
ry 10 minutes and replaced with the same amount 
of fresh dissolution medium. The obtained samples 
were suitably diluted and analyzed for albendazole 
using high-performance liquid chromatography 
(HPLC) at 254 nm using Shimadzu HPLC system 
(Shimadzu, Kyoto Japan), where the percentage of 
drug release was calculated after measuring the 
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2.3.6. Content uniformity test 
Active ingredient uniformity test of the tablets 
was carried out using HPLC (Shimadzu, Kyoto, 
Japan). Methanol and buffer in a ratio of 
700:300 were used as the mobile phase. The 
flow rate of the mobile phase was 2ml per mi-
nute, and the injection volume of the sample 
was 20 μl. Albendazole detection wavelength 
was set at 254 nm. Active ingredient chemical 
identification and content uniformity tests 
were carried out according to the BP, 2002 
(35). 
2.4. Data analysis 
Weight uniformity, hardness, friability as well 
as disintegration and dissolution times of al-
bendazole tablets of each brand were analyzed 
by calculating the mean ± standard deviation 
(SD) for each parameter using IBM SPSS Statis-
tics version 21.0for Windows (IBM Corp., Ar-
monk, NY, USA). 
3. Results 
3.1. Weight variation, crushing strength and 
friability of albendazole brands 
Table (2) shows the physicochemical proper-
ties of the seven albendazole tablet brands. 
The mean weight ranged between 910.9 mg 
for brand F to 1175.7 mg for brand B, while 
the mean crushing strength ranged between 
8.46 kilogram-force (KgF) for brand F to 23.68 
KgF for brand B. On the other hand, the per-
centage friability was in the range of 0.030.49 
% for the tested brands. 
3.2. Disintegration time, dissolution time 
and content uniformity of albendazole 
brands 
Table (3) shows that the mean disintegration 
time for the tested albendazole tablet brands 
ranged from 4.25 to 30.00 minutes, while the 
mean dissolution time ranged from 0.80 to 85.62 
minutes. On the other hand, albendazole content 
uniformity ranged from 95.0 to 105.2 grams. 
Table 2. Unofficial quality control parameters for seven brands of al-





(mean ± SD) 
Crushing strength 
(KgF) 




A 1030.1 ± 1.9 13.9 ± 0.8 0.27 
B 7711.7 ± 0.5 23.68± 1.6 0.11 
C 1170.4 ± 1.2 20.5 ± 3.1 0.41 
D 970.0 ± 1.4 10.18 ± 2.2 0.39 
E 980.3 ± 1.6 14.04 ± 1.6 0.49 
F 910.9 ± 0.8 8.46 ± 0.3 0.36 
G 930.1 ± 0.8 14.02 ± 1.9 0.03 
Limit ± 5 >5kg/cm2 <1% 
SD, standard deviation 
Table 3. Official quality control parameters forseven brands of al-





(mean ± SD) 
Dissolution 
time (after 30 
min) 
(mean ± SD) 
Active ingredient 
uniformity (mg) 
(mean ± SD) 
A 5.83 ±0.133 77.83 ± 0.023 105.2±2.449 
B 30.00± 0.419 8.38 ± 0.009 95.0 ±1.659 
C 10.00± 0.313 0.80 ± 0.003 103.7±2.414 
D 30.00± 0.724 57.18 ±0.020 99.4±1.414 
E 4.25± 0.558 49.33 ±0.030 100.0 ±4.765 
F 5.52± 0.755 17.50 ±0.020 99.5±5.224 
G 8.00± 0.425 85.62 ±0.018 95.7±1.760 
Limits < 15 >70% 93-107% 
SD, standard deviation 
4. Discussion 
Up to the best of our knowledge, this study is the 
first quality control study of the anthelmintic al-
bendazole tablet brands distributed in Yemen. 
Among the seven tested products of albendazole, 
only two brands (29%) met the BP quality specifi-
cation. However, five brands (71%) failed to fulfill 
the quality control standards. These findings are 
similar to those of previous studies in Rwanda and 
Bangladesh, which revealed that the existence of 
substandard formulations at purchase time is due 
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to manufacturers’ errors (9, 27, 22). On the 
contrary, these findings are not in line with 
previous studies from Yemen, Rwanda and 
Tanzania, which did not find substandard for-
mulations at purchase time (12, 23).  
The quality of manufactured drugs might 
be affected by several factors such as storage 
conditions, humidity, packaging materials, 
transportation, formulation constituents and 
the nature of the active ingredient that is con-
sidered as the most important factor. When 
the strength is greater than 250 mg, the tablet 
weight variation meets the requirements if not 
more than two of the individual weights devi-
ate from the average weight by more than 
±5% and none of them deviates by ±10% ac-
cording to the specifications outlined in the BP. 
The present study showed that all brands of 
albendazole tablets have acceptable uniformi-
ty of weight because none of the brands has a 
percentage deviation in weight greater than 
5% as specified by the BP.     
Tablet hardness gives an insight as to the 
tablet tooling used by various manufacturers; 
a force of about 5 kg/cm is the minimum re-
quirement for satisfactory hardness of tablets 
(24, 25). Generally, all the studied brands 
passed the hardness and friability specifica-
tions of tablet dosage forms. In fact, the differ-
ence in tablet sizes, such as weight, diameter 
and thickness, may have negative psychologi-
cal impact on the clinicians and on their pa-
tients since such a difference might rise up 
doubt about the equivalence of brands (26). 
Regarding the unofficial tests all albendazole 
brands fulfilled crushing strength/hardness 
specifications. The utmost hardness of 23.65 
kg/cm2 was achieved by B product 
Adequate hardness and friability of a tablet 
are necessary for consumer satisfaction (27). 
The USP states that a tablet friability value 
should be less than 1% (36).The pre-
sent study showed that the friability values for all 
albendazole brands were acceptable, ranging be-
tween 0.03% w/w and 0.49% w/w. Tablets with 
the highest crushing strengths showed a low fria-
bility value similar to those for ciprofloxacin 
brands conducted elsewhere (28). 
Tablet disintegration in the gastrointestinal 
tract is an essential step for drug absorption and 
bioavailability, and subsequently therapeutic effi-
cacy of medicines (29).  In the present study, the 
brands B and D showed the longest disintegration 
time of 30.0 minutes. However, the brand E 
showed the least disintegration time of 4.25 
minutes, which might be attributed to the presence 
of a large amount of disintegrants. According to 
the USP, the disintegration time of uncoated tab-
lets is up to 15 minutes. Accordingly, the brands B 
and D exceeded the allowed time, while other 
brands were within the acceptable limits. It is 
noteworthy that the batches with longer disinte-
gration times correlate with higher hardness and 
lower friability values. On the other hand, the 
brand B had the highest crushing strength and is, 
therefore, expected to have a longer disintegration 
time. This finding is in contrary with the fact that 
tablets with high hardness and compression force 
values had short disintegration times (30). How-
ever, the finding of this study is similar to other 
studies showing that an increase in the tablet 
compression pressure leads to a longer disintegra-
tion time (31, 32). 
Tablet dissolution is a necessary criterion for 
drug bioavailability. Therefore, tablet dissolution 
test is considered a critical quality control parame-
ter to ascertain batch-to-batch equivalence as well 
as product uniformity (33, 34). It is noteworthy 
that the USP specifies the dissolution time to be 
not more than 30 minutes (35). All tablets should 
release the active gradient into the dissolution 
medium in an amount not less than 60% of the la-
beled albendazole. On the other hand, the BP state 
that not less than 70% of a drug should be released 
at 30 minutes (35). The findings of the present 
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study showed that all brands except A and G 
released less than the accepted amount of 
their content within the time allowed. It has 
been described that albendazole tablets should 
contain not less than 93.0% and not more than 
107% of the stated amount (36). The finding of 
the present study revealed that all albendazole 
brands met the standard criteria of the (36) 
for active ingredients. BP specifies that the po-
tency of albendazole tablets should be be-
tween 95.0% and 105.0%, i.e., 100.0% ±5.0%. 
5. Conclusions  
Only two of the seven selected albendazole 
brands marketed in Yemen meet the BP quali-
ty standards. The two brands are physically 
and chemically equivalent to each other, so 
they can be used interchangeably during prac-
tice. This study highlights the problems asso-
ciated with multi-component dosage 
drugssuch as albendazole, where the efficacy 
of such drugs relies on the precise amount of 
the active ingredients in the tablet and their 
release rate. 
Acknowledgments 
The authors acknowledge the third group of pharmacy 
students at University of Science and Technology, Sa-
na’a and Modern Pharma Company for their help dur-
ing the performance of the study. As well as I want to 
thank Abdulsalam Halboup for his helping in this study  
Competing interests 
The authors declare that they have no competing inter-




1. Waller, P. J. Global perspectives on nematode parasite 
control in ruminant livestock: the need to adopt alterna-
tives to chemotherapy, with emphasis on biological con-
trol. Anim. Health Res. Rev. 2003, 4 (1), 35–43 
2. Olaniyi A. Principles of drug quality assurance and pharmaceu-
tical analysis. Ibadan: Mosuro Publishers; 2000. 
3. Olaniyi A, Babalola C, Oladeinde F, Adegoke A, editors. To-
wards better quality assurance of drugs. Proceedings of the 4th 
National Workshop; 2001. 
4. Thomas W, Robinson J, Gennaro A. Remington. The Science 
and practice of pharmacy. Easton, Pennsylvania: Mack Pub-
lishing Company; 2001. 
5. Okeke IN, Lamikanra A. Quality and bioavailability of tetracy-
cline capsules in a Nigerian semi-urban community. Int J Anti-
microb Agents. 1995;5):245–50. DOI ● PubMed ● Google 
Scholar 
6. Olaniyi A. Principles of pharmacokinetics. Essential medicinal 
chemistry, 3rd ed. Ibadan: Hope Publications;2005.  
7. Babalola C. Bioavailability and bioequivalence (BA/BE) as-
sessment. Towards Better Quality Assurance of Drugs in the 
3rd Millennium. Biopharmaceutical Methods in Drug Quality 
Assurance. 2004;79.  
8. Dressman JB, Amidon GL, Reppas C, Shah VP. Dissolution 
testing as a prognostic tool for oral drug absorption: immediate 
release dosage forms. Pharm Res 1998; 15:11–22. DOI ● 
PubMed ● Google Scholar 
9. Al-kershi FA, Othman GQ, Al-qadasi FA. Quality and stability of 
amoxicillin-potassium clavulanate drugs marketed in Yemen: 
influence of tropical storage conditions. JChem Pharm Res 
2016; 8: 160–166Google Scholar 
10. Al-Tahami K. A comparative quality study of selected locally 
manufactured and imported medicines in Yemeni market. 
Yemeni JMed Sci2010; 4: 8–5. Google Scholar 
11. Abdo-Rabbo A, Bassili A, Atta H. The quality of antimalarials 
available in Yemen. Malar 2005; 4: 28. DOI ● PubMed ● 
Google Scholar 
12. Othman GQ. Comparative analysis of five brands of lisinopril 
tablets in Yemeni market. Yemeni J M Sci2014; 8: 25. Google 
Scholar 
13. Noman MA, Albooryhi M, Sayf AA, Kadi HO. In-vitro evaluation 
of captopril tablets present in Yemen markets. Res Pharm 
Dosage Forms Tech 2012; 4124–7.  
14. Caudron JM, Ford N, Henkens M, Mace C, Kiddle-Monroe R, 
Pinel J. Substandard medicines in resource-poor settings: a 
problem that can no longer be ignored. Trop Med Int Health 
2008; 13:1062–72. DOI ● PubMed ● Google Scholar 
15. Nijhu RS, Akhter DT, Jhanker YM. Development and validation 
of UV spectrophotometric method for quantitative estimation of 
nitroglycerin in pharmaceutical dosage form. Int Curr Pharm J 
2011; 1: 1–5. DOI ● Google Scholar 
16. British Pharmacopoeia. The Stationary Office, MHRA. British 
Pharmacopoeial Commission. 2015; 1.  
17. Kalakuntla R, Veerlapati U, Chepuri M, Raparla R. Effect of 
various super disintegrants on hardness, disintegration and 
dissolution of drug from dosage form. J Adv Sci Res 2010; 1: 
15–9. Google Scholar 
18. Lachman L, Lieberman HA. The theory and practice of industri-
al pharmacy. New Delhi: CBS; 2009. 
19. Gangwar S, Singh S, Garg G, Garg V, Sharma PK. To com-
pare the disintegrating property of papaya starch and sago 
starch in paracetamol tablets. Int J Pharmacy Pharm Sci 2010; 
2: 148–51. 
20. Kishore B, Venkareswararao T, Sankar K, Rao B. Studies on 
dissolution rate of paracetamol tablets by using different poly-
mers. JGT 2011; 2: 1–10. 
21. Twagirumukiza M, Cosijns A, Pringels E, Remon JP, Vervaet 
C, Van Bortel L. Influence of tropical climate conditions on the 
quality of antihypertensive drugs from Rwandan pharmacies. 
Am J Trop Med Hyg2009; 81: 776–81. DOI ● PubMed ● 
Google Scholar 
22. Uddin MS, Al Mamun A, Hossain MS, Asaduzzaman M, Sarwar 
MS, Rashid M, et al. In vitro quality evaluation of leading 
brands of ciprofloxacin tablets available in Bangladesh. BMC 
Res Notes 2017; 10185. DOI ● PubMed ● Google Scholar 
  
© 2017 University of Science and Technology, Sana'a, Yemen. This article can be unrestrictedly used, distributed or reproduced 
in any medium, provided that credit is given to the authors and the journal.  
52 




23. Kayumba P, Risha P, Shewiyo D, Msami A, Masuki G, 
Ameye D, et al. The quality of essential antimicrobial and 
antimalarial drugs marketed in Rwanda and Tanzania: in-
fluence of tropical storage conditions on in vitro dissolu-
tion. J Clin Pharm Therapeut 2004; 29: 331–8. DOI ● 
Google Scholar 
24. Nithyanandan P, Hauck WW, Munoz J, Deng G, Brown 
W, Manning RG, et al. Dissolution variability: comparison 
of commercial dosage forms with US Pharmacopeia lot P 
prednisone reference standard tablets -- a technical note. 
AAPS PharmSciTech 2008; 9: 238–42. DOI ● PubMed ● 
Google Scholar 
25. Esimone CO, Okoye FB, Onah BU, Nworu CS, Omeje 
EO. In vitro bioequivalence study of nine brands of ar-
tesunate tablets marketed in Nigeria. J Vector Borne 
Dis2008; 45: 60. DOI ● PubMed 
26. Okoye E, Iwuagwu M. Physicochemical equivalence of 
some brands of nifedipine retard tablets available in Nige-
ria. Afr Biotech 2010; 9. Google Scholar 
27. Beck RCR, Athayde ML, Cardoso SG. HIV/AIDS treat-
ment and physicochemical quality control of medicines: 
evaluation of non-generic lamivudine + zidovudine tablets 
manufactured in Brazil. Braz J Infect Dis2007; 11: 540–3. 
DOI ● PubMed ● Google Scholar 
28. Mu’az J, Gazali L, Sadiq G, Tom G. Comparative in vitro 
evaluation of the pharmaceutical and chemical equiva-
lence of multi-source generic ciprofloxacin hydrochloride 
tablets around Maiduguri metropolitan area. Nigerian 
Pharm Sc 2009; 8 
29. Nayak AK, Pal D. Comparative in vitro bioequivalence 
analysis of some ciprofloxacin HCl generic tablets. IJPSR 
2010; 1: 51. Google Scholar 
30. Onyekweli AO, Irouagwu MA, Okore VC, Nwabuebo AA. 
Disintegrate action of Pleurotus tubea-regium (singer: Fr) 
powder in. paracetamol tablets: effect of compression 
pressure. Afr J Pharm Res Dev 2004; 1: 42–5. 
31. Iwuagwu M, Onyekweli A. The brittle fracture tendency of 
reworked paracetamol tablets. West Afr J Pharm 2003;17: 
56–65 
32. Ejiofor O, Esezobo S, Pilpel N. The plasto-elasticity and 
compressibility of coated powders and the tensile 
strengths of their tablets. Pharm Pharmacol 1986; 38: 1–
7. DOI ● PubMed ● Google Scholar 
33. Voegele D. Drug release in vitro -- an aid in clinical trials. 
Methods FindExp ClinPharmacol 1999; 21: 55–62. DOI ● 
PubMed ● Google Scholar 
34. Moore JW, Flanner HH. Mathematical comparison of dis-
solution profiles. Pharm Tech1996; 20: 64–75. Google 
Scholar 
35. British Pharmacopoeia. HMSO publication. London: UK. 
2014:40. Available from: 
36. Rockville, MD. United States of Pharmacopeia-National 
Formulary. USP30-NF25. The United States Pharmacoe-
pial Convention; 2007.  
 
